I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EURETINA 2024

-
Coming soon
06:00 AM
Duration 4mins Audio-Narrated Free Paper Session
Early Fluid Resolution in the Head-to-Head Phase of the TENAYA/LUCERNE Trials Is Associated With Short- and Long-Term Extended Durability in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼
Gallego-Pinazo R, Amador M, Dagincourt N, Stoilov I, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes From the YOSEMITE/RHINE Trials and Real-World FARETINA/FARWIDE Studies in Patients With DME
Finger R, Manoharan N, Kim J, Amador M, Willis J,Stoilov I, Mar F, Gibson K, Abreu F, Tabano D, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in Diabetic Macular Edema (DME)
Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study
Pavesio C, Suhler E, Lin P, Pauly-Evers M, Willen D, Holmes W, Storti F, Barekati Z, Gott T, Passemard B, Macgregor L, Sharma S, Fauser S, Mesquida M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Patient Preference for the Port Delivery System With Ranibizumab vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema
Chang M, Koh A, Marcus D, Boldonado K, Daly A, Hill L, Menezes A, Prager A, Wallenstein G, Tian K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Port Delivery System (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial
Graff J, Awh C, Regillo C, Bobbala A, Dakouras A, Howard D, Gune S, Menezes A, Rabena M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With Neovascular Age-Related Macular Degeneration (nAMD) in the United Kingdom: 1 Year Results From the FARWIDE-nAMD Study
McKibbin M, Talks J, DeSalvo G, Patel P, de Silva S, Gale R, Varma D, Dayal P, James N, Shah N, Downey A, Dodds M, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Audio-Narrated Free Paper Session
Reduction in Pigment Epithelial Detachment With Faricimab▼ vs Aflibercept: A Subgroup Analysis of Patients with Large and Serous PEDs From the Pooled Phase 3 TENAYA and LUCERNE trials
Khanani A, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai T, Lim J, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:05 AM
Duration 5mins Speakers Corner
Characterisation of Fibrosis in the Archway Trial: The Impact of Continuous Delivery of Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Chakravarthy U, Holekamp N, Blotner S, Cavichini M, Garcia Armendariz B, Kanku M, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:36 AM
Duration 5mins Room: 118 / 119
Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of Neovascular Age-related macular degeneration (nAMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)
Chang M, Pieramici D, Pearce I, Campochiaro P, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:42 AM
Duration 5mins Room: 118 / 119
Faricimab▼ in DME: Results from the RHONE-X Long-Term Extension Trial
Schlottmann P, Khanani A, Lai T, Kotecha A, Sim D, Harrell E, Abreu F, Tang Y, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:18 PM
Duration 5mins Room: 118 / 119
12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: FARETINA-AMD
Lim J, Tabano D, Ali F, Ko S, Borkar D, Leng T, Myrick A, Shaia J, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 PM
Duration 5mins Speakers Corner
12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Sheth V, Tabano D, Ali F, Ko S, Borkar D, Leng T, Myrick A, Shaia J, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:00 AM
Duration 5mins Room: 118 / 119
Impact of Early Intraretinal Fluid Reduction on Two-Year Outcomes in Diabetic Macular Edema
Lim J, Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:12 AM
Duration 5mins Room: 118 / 119
Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With Diabetic Macular Edema (DME) in the United Kingdom: 1-Year Results From the FARWIDE-DME Study
Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L, Kiire C, Pearce I, Dayal P, James N, Shah N, Downey A, Dodds M, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:18 AM
Duration 5mins Room: 118 / 119
Visual Acuity and Anatomic Improvements at Week 24 Were Maintained Through Week 72 With Faricimab▼ Treat-and-Extend Dosing in the Phase 3 BALATON and COMINO RVO Trials: Patient Case Profiles and Results Summary
Dinah C, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:50 AM
Duration 5mins Speakers Corner
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: 2-Year Data From the Phase 3 Pavilion Trial
Khanani A, Chang M, Holmes W, Santhanakrishnan A, Tian K, Wetzel-Smith M, Latkany P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:00 AM
Duration 5mins Room: 118 / 119
Analysis of Extended Interval Treatment Outcomes, Potential for Q20W Dosing and Predictors of Treatment Durability in nAMD With Faricimab▼ From the TENAYA/LUCERNE Trials
Koh A, Ambresin A, Patel P, Singer M, Dagincourt N, Hill L, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:06 AM
Duration 5mins Room: 118 / 119
Key Clinical Outcomes With Faricimab▼ in Treatment-naïve Patients With nAMD: Results From the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies
Souied E, Avery R, Haug S, Tabano D, Chi G, Amador M, Kotecha A, Margaron P, Yang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:54 AM
Duration 5mins Room: 118 / 119
The Clinical Impact of Continuous Delivery of Ranibizumab With the Port Delivery System (PDS) in Neovascular Age-Related Macular Degeneration (nAMD)
Zinkernagel M, Rachitskaya A, Holekamp N, Dauletbekov D, Blotner S, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:20 AM
Duration 5mins Grand Auditorium
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, Downey A, Finger R, Gallego-Pinazo R, Koh A, Ishida S, Lövestam-Adrian M, Parravano M, Luna Pinto J, Schmitz-Valckenberg S, Sheth V, Shi B, Souied E, Uschner D, Guymer R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:45 AM
Duration 1hr Barcelona, Spain
View the EURETINA symposium "Changing the nAMD Gameplan with Faricimab▼: Dual Pathway, Drying, and Durability"
Holz F, Hamilton R, Lim J, Koh A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:00 PM
Duration 5mins Room: 111
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Phase 2b Trial Exploring Biomarkers of Angiopoietin-2 Inhibition in Patients With Diabetic Macular Edema
Ziemssen F, Amador M, Dieckmann A, Gibson K, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:06 PM
Duration 5mins Room: 111
Greater Reduction in Hard Exudates With Faricimab▼ vs Aflibercept in Patients With DME: Biomarker Results From the Phase 3 YOSEMITE/RHINE Trials
Dinah C, Vujosevic S, Goldberg R, Ip M, Rahimy E, Amador M, Gibson K, Glittenberg C, Maunz A, O'Leary O, Uschner D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:12 PM
Duration 5mins Room: 111
Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials
Ambresin A, Gibson K, Sim D, Hill L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:45 PM
Duration 1hr Barcelona, Spain
View the EURETINA symposium "Changing the DME Gameplan with Faricimab▼: Dual Pathway, Drying, and Durability"
Schlottmann P, Vujosevic S, Pearce I, Udaondo P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 1hr Barcelona, Spain
View the EURETINA symposium "Is Continuous Drug Delivery the Key to Transforming Long-term Outcomes in Retinal Diseases?"
Figueroa M, Hillier R, Graff J, Chang M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:06 PM
Duration 5mins Room: 118 / 119
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Fonollosa A, Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar